ANAPRINT
Financiado
Additive Printing for Cell Based Analysis
The Project shall develop a unique manufacturing solution for the automated production of complex cell models widely used by industry to test biological activity and biosafety. No means of scalable manufacture presently exists.
T...
The Project shall develop a unique manufacturing solution for the automated production of complex cell models widely used by industry to test biological activity and biosafety. No means of scalable manufacture presently exists.
The technical solution is to assemble cell models by additive manufacturing; to control the resident cells’ locations within these 3D models; to supply the models to customers as pre-assembled, frozen products. The result shall be an analytical tool which, unlike current practice, does not compromise analytical output for convenience, but combines high predictive value and low cost with exceptional user-friendliness.
The solution is unique, proprietary and highly positive-disruptive in its industrial sector. Its achievement will be measurable in this Project as an exemplifying, printed hepatotoxicity assay with wide application in drug discovery and biosafety testing. An SME Instrument Phase 1 Project advanced the core printing technology delivering this solution to TRL7, and developed a business plan for its exploitation.
That business plan confirmed the wide, cross-industry application of cell-based analysis, from preclinical drug discovery through natural products/food to medical devices and nanosafety, and mapped the advantages of additively-manufactured products onto demonstrable industry trends and customer needs.
The business plan and its underpinning technology are founded in the applicant’s long-term strategic goals, evidenced by profitable business in the target market from proprietary cell-based services, and by ancillary technology developments, also to TRL7 and supported by UK national funding, which create unique competitive advantage.
The outcome of this Phase 2 Project will be a mature cell-based manufacturing technology, its demonstrable application in a commercial environment, and the assembly of a corporate infrastructure ready to take the Project’s manufacturing solution into a well-scoped and lucrative marketplace.
ver más
Duración del proyecto: 36 meses
Fecha Inicio: 2015-10-11
Fecha Fin: 2018-10-31
Fecha Fin: 2018-10-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
AvantiCell Science Ltd
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
1.09M€ |
Participante